Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

By Steven J. Cohen, C. Punt, N. Iannotti, B. Saidman, K. Sabbath, N. Gabrail, J. Picus, M. Morse, E. Mitchell, M. Miller and 4 more. Journal of Clinical Oncology, 2008

1,788 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/3ed2c1508195b1dfd38351b4e87a46657b8ff077

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Jing Yang
2. M. Nieto
3. R. Weinberg

In Oncology

1. Jing Yang
2. J. Tsai
3. Fortunato Ciardiello
4. R. Weinberg
5. M. Nieto

Citations in the corpus

• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “Although the levels of CTCs as assessed (mostly using the CellSearch system) have been shown to correlate with prognosis in patients with mCRC [117], the clinical utility of CTC assessments in patients with mCRC has hardly been explored.”
• Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, background): “A similar positive selection cum enrichment technology for CTCs obtained from LB samples is the CellSearch system [15, 22].”
• Epithelial–mesenchymal plasticity in carcinoma metastasis (2013, background): “Studies in patients with metastatic breast and colorectal cancer showed that CTCs serve as an independent predictor of progressionfree survival and overall survival (Christoffersen et al. 2007; Cohen et al. 2008).”